Physician profile
Wesley Tk Kerr
NPI 1720506272
$54,315.44
in general payments reported to CMS, 2019-2025
7 companies · $23K in 2025
The $23K reported for 2025 was more than what 95% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $207 · 2022: $8,823 · 2023: $4,095 · 2024: $18K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $43K · Food and Beverage: $1,445 · Honoraria: $1,020 · Travel and Lodging: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $42,699.00 |
| Food and Beverage | $1,445.12 |
| Honoraria | $1,020.00 |
| Travel and Lodging | $121.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $23,723.16 | 2021-2025 | Xcopri |
| Neurelis, INC. | $12,328.87 | 2024-2025 | Valtoco |
| Ucb, INC. | $7,542.02 | 2021-2025 | Fintepla |
| Ucb Sa | $3,850.00 | 2024 | Fintepla |
| Jazz Pharmaceuticals INC. | $3,530.62 | 2024 | |
| Azurity Pharmaceuticals, INC. | $2,040.00 | 2024 | |
| Ceribell, INC. | $1,300.77 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Kerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.